BrainOmega is a Generative AI company working across pharma and biotech. Our foundation models help research teams design, evaluate and prioritise new medicines before they reach the lab, with the evidence for every result shown beside it.
Most discovery cost is spent on candidates that fail. Designing and evaluating them in software first means research budgets and lab time go to the ones most likely to succeed.
Shorter design–evaluate cycles for drug and vaccine discovery, because ideas are tested in software before they are made.
Fewer compounds and sequences synthesised and screened only to be dropped later.
Weak candidates are filtered out before in vitro and in vivo work begins.
Better-informed choices about which candidates move forward.
Two products on our own foundation models, behind one sign-in and one workspace.
The models underneath both products, built and trained by BrainOmega for chemistry and RNA biology.
A Generative AI workspace for small-molecule programmes, from target to shortlist.
Discovery across RNA classes, from microRNAs and tRNA fragments to circular RNAs and mRNA neoantigens.
The same four steps for a small-molecule programme or an RNA project, and nothing to rebuild in your existing stack.
Set the target, the modality and the constraints that matter to your programme.
Our models propose candidate molecules or RNA sequences that fit the brief.
Each candidate is scored on the properties that decide its fate, with the evidence and confidence shown.
Rank, compare and export the shortlist for your scientists and your lab.
What research, governance and investment teams ask us about, and how the platform answers.
Built and trained in-house for chemistry and RNA biology, so we can explain and improve every layer of the stack.
Each prediction shows the data and the rule behind it, so scientists can check it rather than take it on trust.
Every value comes from a versioned pipeline. Run it again and you get the same answer, which is what reviewers and regulators expect.
Results come with their confidence, and a missing result is reported as missing, never as a negative.
Two modalities in one workspace, so programmes are not split across disconnected vendors.
The platform supports medicinal chemists and biologists. Every output is a suggestion to review, never a black-box decision.
We work with pharma, biotech, academic and investment teams, and shape each engagement around the programme rather than a fixed package.
Run programmes on the platform together, with shared milestones and IP terms agreed up front.
Lean teams use BrainOmega as their discovery engine: generation, evaluation and prioritisation from day one.
Joint projects with university and institute groups working on drug and RNA discovery.
Briefings for venture and corporate venture teams on the platform, the products and the roadmap.
Pharma, biotech, academic group or investor: send us a short note and the right person on our team will reply within one business day.
We are happy to walk you through the platform on one of your own questions, discuss a partnership, or brief you on the company.
